Clinical Trial Update: Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab plus paclitaxel or ramucirumab as second-line therapy for gastroesophageal junction adenocarcinoma and stomach adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Stomach
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Avelumab (avelumab)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: P. C. Thuss-Patience | Conditions: Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Stomach | Phase 2 | Status: UNKNOWN